SPECIAL REPORT
The Role of Advanced Meal Replacements in Weight Loss Programmes
Almased速: A Meal Replacement for Weight Loss and Improved Diabetic Control The Central Role of the GP in the Obesity Epidemic The Importance of Modest Weight Loss and a Multicomponent Diet Programme 速
Sponsored by
The Role of Low Calorie Diets as Part of Weight Loss Programmes Weight Loss: A Summary of Where We Are
Published by Global Business Media
AAMeal MealReplacement Replacement Weight A Mealfor Replacement for WeightControl Control
for Weight Control Nourishes Nourishesthe thebody bodyand andends endsthe thedieting dietingcycle cycle
6 things to know 6 things No.1any 6 thingstotoknow know .1.1y rm eo GN o In N about Almased about Almased about Almased nathe ae ny dieting cycle w Nourishes rm GeGrem nends Nourishes the the body N Io nw I body and and ends the dieting cycle N w e w e N oowTwo NK NN Retains muscle mass while Retains muscle mass while • Retains muscle mass while
A Meal Replacement Control 66 things things to to know knowfor Weight .1 burning fatfat andand losing weight burning losing weight burning fat and losing weight
UK o ThTeheUK tThToe U
o . 1 N o Nourishes the body and ends the dieting cycle N about Almased y n Suitable Diabetics - Keeps blood sugar Suitable forfor Diabetics - Keeps blood sugar a about Almased m y r n e • Suitable for Diabetics - Keeps IInn G balanced Germa balanced blood sugar balanced eew w A diet programme Now N Ato diet programme N 6 things know w Retains muscle mass while o Retains muscle mass while • A diet programme where you N Boosts thethe metabolism Boosts metabolism • Boosts the metabolism
Retains muscle mass while where won‘t where youyou won‘t burning fat and weight won‘t feel hungry burning fat and losing weight about Almased feelfeel hungry burning fathungry and losing losing weight
hheeoU K1 U.K TToo TTN rmany In Ge
w
Now Ne
Superb Sports • Boosts Superbthe Sports nutrition Superb Sports metabolism Boosts the metabolism Boosts the metabolism nutrition nutrition mass while • Does notRetains containmuscle any artificial flavours, K o The U Does not contain anysugar T burning fat and losing weight Suitable for Diabetics Keeps blood Does not contain any Suitable for Diabetics Keeps blood sugar fillers, added sugars or preservatives Suitable for Diabeticsartificial - Keeps blood sugar flavours, artificial flavours, and is gluten-free balanced balanced balanced fillers, added sugars Boosts the metabolism fillers, added sugars or or preservatives preservatives andand is is To place an order A diet programme A programme gluten-free. Suitable forgluten-free. Diabetics - Keeps blood sugar A diet dietcall: programme please (0044) 20 7969 1886 won‘t where you won‘t balanced orwhere email:you order@almased.co.uk To place an order where you won‘t To place an order please call: 020 7969 1886 www.almased.co.uk feel hungry feel hungry please call: 020 7969 1886 feel hungry
A diet programme or email: order@almased.co.uk or email: order@almased.co.uk ®where you won‘t Superb Superb Sports Almased : 10 Proven Statements Superb Sports Sports feel hungry nutrition
nutrition nutrition
All core claims about Almased have now been scientifically validated. Eight scientists have drafted 10 statements about the effects of this powdered health food.
3.
Superb Sports
Almased supports healthy insulin levels, while stimulating fat reduction and inhibiting fat storage.
8.
50 g of Almased per day supports healthy blood parameters (e.g. blood sugar, HbA1c value).
Does contain Does not contain any Does not notnutrition contain any any S u p e4.r bThentissue u t rhormone i t i o nghrelin, f o rwhich v iisr t u a l9.ly A aweight l l loss y o programme u r c u swith t oAlmased mers Almased can do a lot more than just S help produced byi stomach cells, is an indicator supports healthy cholesterol u p e r b n u t r i t o n f o r v i r t u a l ly a l l y o u r c u s t oandm e r s artificial flavours, artificial flavours, artificial flavours, people lose weight. This is the conclusion of of the feeling of satiety. Almased supports triglyceride levels. eight German scientists who have looked into ghrelin levels, thereby reducing appetite Does not contain any 10. A weight loss programme with Almased fillers, added sugars or the fillers, effects of thisadded health food.sugars Together theyor for long periods. fillers, added sugars or lowers both systolic and diastolic blood artificial flavours, have drafted the following statements. They pressure. preservatives and preservatives and is isfrom 5. Almased has a positive effect on the body confirm all core claims about Almased, preservatives and is added sugarsfatorvs. lean tissue ratio. If combined with Summary: Almased has a beneficial effect the breakdown of fat fillers, and retention of muscle physical activity, it can significantly reduce gluten-free. gluten-free. mass to the beneficial impact upon hormone gluten-free. upon all components of metabolic syndrome. preservatives levels and blood pressure and therefore to and is fat deposits around the abdomen and This product is not intended to diagnose, treat, cure or prevent any disease.
This product is not intended to diagnose, treat, cure or prevent any disease.
The Pharmacist_03.indd 1
02.09.13 10:02
The Pharmacist_03.indd 1
02.09.13 10:02
hips.
gluten-free. To an Toplace place an order 6. In a weight loss programme, Almased placecontains anorder order 1.ToAlmased pure soya protein, helps to burn body fat without reducing yogurt and raw honey. A special pleasecall: call:To 020 7969 1886 please 020 7969 1886 please call: 020 7969 1886 muscle mass. place an order processing method preserves the essential amino acids incall: Almased. 7. please 020 7969 1886 or email: order@almased.co.uk or email: order@almased.co.uk or email: order@almased.co.uk Weight loss achieved with Almased is reducing the risk of metabolic syndrome.
2.
helpful in changing nutritional behaviour Obesity is associated with a severely or email: order@almased.co.uk and keeps the weight off long-term. increased leptin level, which, in turn, is linked to insulin resistance and considered to be a cause of metabolic disorders, such as diabetes mellitus. Almased supports a healthy leptin level, thereby favourably influencing the risk factors.
It is recommended that it be used for at least 6 weeks. To lose weight, Almased should be used as a meal substitute (1 to 2 x 50 g daily). Even just 50 g once a day brings about an improvement in metabolic biomarkers. For full scientific data relating to these statements, please contact us.
SSuuppeerrbSbunnpueurttbrriinttiiuootnn r i tffioo o rn vf oi rr tvui a r tlulya l a lyl la lyl oyuoru rc u c us st o t om meerr ss This product product is not not intended any This to treat, cure or This is product is not intended to diagnose, or prevent anydisease. disease. This product is not intended intended to diagnose, diagnose, treat,treat, curecure or prevent prevent any disease.
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
SPECIAL REPORT
The Role of Advanced Meal Replacements in Weight Loss Programmes
Contents Foreword
2
Dr Robert Sykes, Editor
Almased®: A Meal Replacement for Weight Loss and Improved Diabetic Control The Central Role of the GP in the Obesity Epidemic The Importance of Modest Weight Loss and a Multicomponent Diet Programme The Role of Low Calorie Diets as Part of Weight Loss Programmes
®
Sponsored by
Weight Loss: A Summary of Where We Are
Published by Global Business Media
Published by Global Business Media Global Business Media Limited 62 The Street Ashtead Surrey KT21 1AT United Kingdom Switchboard: +44 (0)1737 850 939 Fax: +44 (0)1737 851 952 Email: info@globalbusinessmedia.org Website: www.globalbusinessmedia.org Publisher Kevin Bell Business Development Director Marie-Anne Brooks Editor Dr Robert Sykes Senior Project Manager Steve Banks Advertising Executives Michael McCarthy Abigail Coombes Production Manager Paul Davies For further information visit: www.globalbusinessmedia.org
Almased®: A Meal Replacement for Weight Loss and Improved Diabetic Control
3
Almased UK Ltd
Obesity and Metabolic Disorders The Product: Three Key Ingredients in a Proprietary Blend The Holy Grail: Losing Weight and Keeping It off The Basics: Almased® and Weight Loss Demonstrable Weight Loss Optimal Levels of Hormones That Influence Satiety Almased® for Type 2 Diabetes: A Therapeutic Food? Weight Loss and Improved Glycaemic Control Conclusions: Could Almased® Be the Perfect Fit For Weight Loss in Diabetes?
The Central Role of the GP in the Obesity Epidemic
10
Dr Robert Sykes, Editor
The Cost to Society Something Needs to Change Enter Primary Care …. The Call to Action
The Importance of Modest Weight Loss and a Multicomponent Diet Programme
14
Susan Thomas, Medical Correspondent
Any Weight Loss Is Good, but It Only Needs To Be Modest Obesity Has a Multi-Dimensional Pathogenesis Treatment Approaches Must Evolve Treatment Should Focus On the Multidimensional Nature of Obesity
The opinions and views expressed in the editorial content in this publication are those of the authors alone and do not necessarily represent the views of any organisation with which they may be associated.
The Role of Low Calorie Diets as Part of Weight Loss Programmes
Material in advertisements and promotional features may be considered to represent the views of the advertisers and promoters. The views and opinions expressed in this publication do not necessarily express the views of the Publishers or the Editor. While every care has been taken in the preparation of this publication, neither the Publishers nor the Editor are responsible for such opinions and views or for any inaccuracies in the articles.
Low-Fat Diets High Protein Diets Low Carbohydrate and Low Glycaemic Index Diets Meal Replacements, Liquid Diets and Very Low-Calorie Diets Recommended Dietary Strategies for Weight Loss
18
G A Hood
Weight Loss: A Summary of Where We Are
22
Dr Robert Sykes, Editor © 2014. The entire contents of this publication are protected by copyright. Full details are available from the Publishers. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical photocopying, recording or otherwise, without the prior permission of the copyright owner.
What is Known? What Next? Conclusions
WWW.PRIMARYCAREREPORTS.CO.UK | 1
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Foreword O
VERWEIGHT AND obesity represent major
weight loss, as stressed by the National Institute for
burdens to our society, with over two-thirds
Health and Clinical Excellence and the Department of
of adults and a quarter of children in these at-risk
Health, which seek to ensure a sustained downward
categories. Indeed, an increased body mass
trend in obesity by 2020. Given that over 90% of patient
index represents a significant risk factor for many
contact with the NHS is in primary care, the focused
of the major health problems that are blighting
input of general practitioners is crucial. Next, we take
modern society, most notably type 2 diabetes
a closer look at the advances in our understanding of
mellitus and cardiovascular disease, including
the multi-dimensional nature of weight gain and loss.
hypertension, ischaemic heart disease, and
Although clearly a disorder of energy balance (too
stroke. This increased societal morbidity places
much in versus too little out), it appears to be clear
increased strains on an already stretched National
that humans have evolved a complex system with
Health Service. Therefore, we must evolve suitable
multiple redundancies that were designed to serve
strategies to deal with the modern epidemic of
us in resource-scare environments; sadly, the modern
obesity. Many strategies are available, ranging
Western environment is anything but resource scarce.
from dietary manipulation and calorie restriction to
In the fourth article, we then look at the popular role
medication, behavioural therapy, health legislation
of low calorie diets and some of the evidence behind
and increased exercise. Given that focusing on the
their use. From low fat to high protein diets, the low
full spectrum of the available responses would be
glycaemic index diet and meal replacements, it can
beyond the scope of this report, we focus instead
be difficult to know what to recommend to patients.
on public health and primary care, with a particular
This article therefore seeks to clarify this issue. Finally,
focus on dietary manipulation.
in the fifth article, I summarize the core messages of
This Special Report opens with an article that looks at
this report and briefly consider some future needs.
the role of Almased in the management of weight loss
Although this report does not aim to be exhaustive, it
and diabetes. The article outlines the growing evidence
does strive to give the clinician some useful information
base underpinning this meal replacement and
to guide practice, policy and service commissioning.
discusses its clinical usefulness. This is followed by an article that emphasises the importance of primary care in the management of overweight and obese patients. Notably, the financial and clinical cases are made for
Robert Sykes Editor
Dr Robert Sykes qualified with a degree in medicine (MBChB with Honours) from the University of Liverpool in 2004. As an undergraduate he was awarded the prestigeous George Holt Medal for High Academic Achievement, along with commendations for a number of clinical reviews. As a postgraduate, he entered into a GP Vocational Training Scheme, before opting to pursue a portfolio career. At present he is the Executive Editor of the Doctors Support Network (www.dsn.org.uk registered charity 1103741), works as a contracted Editorial Consultant for Enago (www.enago.com), and has established DocRob writing and editorial services (www.docrob.co.uk).
2 | WWW.PRIMARYCAREREPORTS.CO.UK
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Almased®: A Meal Replacement for Weight Loss and Improved Diabetic Control Almased UK Ltd
FIGURE 1. THE 10 VALIDATED CLAIMS OF ALMASED
Eight scientists drafted the following 10 statements on the effects of Almased on the metabolic syndrome
Almased Retains Muscle Mass While Burning Fat & Losing Weight
1 Almased contains pure soya protein, yogurt and raw honey. A special processing method preserves the essential amino acids in Almased. 2 Obesity is associated with a severely increased leptin level, which, in turn, is linked to insulin resistance and considered a cause of metabolic disorders, such as diabetes mellitus. Almased supports a healthy leptin level, thereby favourably influencing the risk factors. 3 Almased supports healthy insulin levels, while stimulating fat reduction and inhibiting fat storage. 4 The tissue hormone ghrelin, which is produced by stomach cells, is an indicator of the feeling of satiety. Almased supports ghrelin levels, thereby reducing appetite for long periods. 5 Almased has a positive effect on the body fat vs. lean tissue ratio. If combined with physical activity, it can significantly reduce fat deposits around the abdomen and hips. 6 In a weight loss programme, Almased helps to burn body fat without reducing muscle mass. 7 Weight loss achieved with Almased is helpful in changing nutritional behaviour and keeps the weight off long-term. 8 50 g of Almased per day supports healthy blood parameters (e.g. blood sugar, HbA1c value). 9 A weight loss programme with Almased supports healthy cholesterol and triglyceride levels. 10 A weight loss programme with Almased lowers both systolic and diastolic blood pressure.
Obesity and Metabolic Disorders Obesity is a growing problem globally, representing one of the most important health issues to face our population over the coming decades. With growing prosperity and improvements in agriculture and farming coupled with increasingly sedentary lifestyles, Western societies are suffering from a growing range of metabolic problems related to obesity. The scale of this problem requires active intervention to stem the tide. To this end, Almased® began its life at a kitchen table in 1980 when the holistic therapist Hubertus Trouillé blended a recipe to help his many patients with a slow metabolism and to reduce unhealthy body fat. From those humble beginnings – one man wanting to help his patients – Almased® has become Germany’s best-selling diet product, but remains a family business at its core. With a strong belief in the
potential therapeutic benefits of Almased®, the company have since spent much of the last 20 years demonstrating its effectiveness in managing a host of problems, not least of which are the original metabolic indications1. This article seeks to describe some of the key facts in this area (Figure 1), focusing specifically on the benefits of Almased ® in weight loss programmes for overweight,obese and type 2 diabetic patients.
The Product: Three Key Ingredients in a Proprietary Blend
Scientific Reference Deibert P, et al (2004). Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soya-protein diet. International Journal of Obesity: 28 (10); 1349-52. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
Almased® is a powder made from high quality soya, probiotic yogurt and enzyme rich honey (Figure 2). Blending raw ingredients during a fermentation process creates a synergistic effect, with evidence now supporting the original WWW.PRIMARYCAREREPORTS.CO.UK | 3
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Almased® makes it easier to lose weight and keep it off because it is low in calories, stimulates the fat burning process and keeps you feeling full for longer
assertions that Almased® has positive effects on the metabolism. Indeed, research has confirmed the beneficial effects of Almased® on body weight, metabolism, performance levels and several diseases. Crucially, Almased® is not a short-lived fad diet, but is now an established component of a healthy lifestyle for many people, with a growing scientific basis. The combination of raw ingredients in Almased® produces synergistic effects. For example, analyses suggest that natural bioactive peptides are formed from the soya and yogurt protein that have beneficial effects on lipid metabolism, promote healthy cell formation and inhibit the deposition of fat. Almased® is therefore very different to currently available meal replacements.
FIGURE 2. NUTRITIONAL INFORMATION AND DIRECTIONS The basic plan: to lose weight, one or two Almased shakes can be used to replace a main meal at any time of the day for at least 6 weeks. Each meal consists of 50g powder mixed with 2 teaspoons of oil rich in essential fatty acids. Other meals should be high in protein. However, just 50g once a day brings about an improvement in metabolic biomarkers.
The Holy Grail: Losing Weight and Keeping It off Imagine a typical clinical scenario: you are presented with an overweight patient approaching middle age – they have some borderline metabolic issues, perhaps some raised cholesterol and triglycerides, and maybe a personal or family history of type 2 diabetes. They are also overweight, with central obesity: the middle-aged spread. They keep trying to diet, but they say that they just cannot keep the weight off. Consequently, their weight increases and decreases in cycles, with their motivation deteriorating with each failed cycle. You may have tried medications and formal diet programmes, but the outcome is the same each time – initial weight loss that is not sustained. It seems that weight loss is easy, when motivated, but that keeping it off is difficult. You need a new approach.
The Basics: Almased® and Weight Loss Although early scientific studies of Almased® validated its superior performance compared with traditional weight loss programmes, it was in 2000 that this came to the fore (Figure 3)2. Almased® makes it easier to lose weight and keep it off because it is low in calories, stimulates the fat burning process and keeps you feeling full for longer.
Demonstrable Weight Loss A study in Germany showed the effectiveness of a very low calorie diet (VLCD) on body weight and shape among 12 overweight participants consuming Almased ® for breakfast and dinner with a normal, low-fat midday meal for four weeks. The participants lost an average 4.8 kg (10.6 lbs), which researchers attributed to improvements in levels of the regulating hormones insulin and leptin2. In 2004, another research team examined the effects of the Almased® diet on body composition. Their six-month study showed that the participants lost fat, but unlike with other diets they also retained muscle mass, which is itself key to maintaining a healthy metabolism.3 Furthermore, a comparative study in 2005 documented the superior success of a diet including Almased® over several conventional programmes. After twelve months, the Almased® diet resulted in a significantly greater weight loss when compared with the the Ornish, Zone (40-30-30), Weight Watchers, orlistat, or Atkins diets (average weight loss: 6.4 kg versus 3.3 kg, 3.2 kg, 3.0 kg, 2.9 kg and 2.1 kg, respectively)4.
4 | WWW.PRIMARYCAREREPORTS.CO.UK
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
FIGURE 3. ADVANTAGES OF USING ALMASED
Almased Reduces Metabolic Syndrome & Cardiovascular Risk Factors
Optimal Levels of Hormones That Influence Satiety Satiety and hunger are under the control of highly complex mechanisms. The control centre in the hypothalamus receives signals from the stomach, intestine and cerebrum to inform us that we are hungry. Three hormones, ghrelin, leptin and insulin, are central to this process (Figure 4)5. Ghrelin is released when the stomach is empty and signals hunger, while leptin reports on the fullness of the body’s fat cells. At the same time, insulin levels must be stabilised at a low level to achieve satiety and optimal fat burning. The longer that insulin levels remains low after consuming food, the longer a person feels full. Importantly, there is growing evidence to suggest that Almased® can lower these three hormones, in effect telling the control centre in the hypothalamus that the patient is not hungry6,7. In a study of 25 overweight women, a diet with Almased® not only resulted in weight loss but also caused an average 40% decrease in both insulin and leptin levels over 24 weeks6. In addition, the “Breakfast Study” of 20127 found interesting effects with an Almased® breakfast on insulin and ghrelin blood levels when compared with a standard high-carbohydrate and low-protein breakfast. After four hours, the insulin and ghrelin levels of participants consuming Almased® were noticeably lower. Thus, in addition to being a VLCD, Almased® has the ability to aid weight loss by creating sustained low ghrelin and insulin
levels, thereby maintaining satiety and keeping hunger under control7.
Almased® for Type 2 Diabetes: A Therapeutic Food? Unsurprisingly, research into the beneficial effects on insulin levels led researchers to consider the role of Almased® in diabetes. Over 3 million people in the United Kingdom suffer from diabetes, of which most are type 2 diabetics. Type 2 diabetes is a metabolic disorder that predominantly occurs in overweight people who become increasingly insulin resistant, and who ultimately develop beta cell dysfunction. Consequently, their cells do not absorb sufficient glucose despite high blood sugar levels – the classic picture of starvation in the midst of plenty. In response to this, more insulin is produced to normalise their blood sugar levels, which encourages fat deposition and inhibits fat breakdown. Given this metabolic milieu of increased fat deposition and increased appetite caused by insulin, it is not surprising that patients with diabetes actually find it harder to lose weight when compared with your typical patient. Despite being a disease caused by obesity, physical inactivity and excessive calorie intake, the medical model of treating type 2 diabetes has tended to focus on intensifying the use of hypoglycemic medication. However, the foundation of long-term therapy should be lifestyle and dietary change, a domain in which Almased® can specifically help.
Scientific Reference Deibert P, et al (2007). Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutrition Journal 6; 31: 1-7. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 5
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
The foundation of
FIGURE 4. ALMASED INFLUENCES KEY NEUROTRANSMITTERS INVOLVED IN APPETITE REGULATION
long-term therapy should be lifestyle and dietary change, a domain in which Almased® can specifically help
“I lost 15lb, which I was very pleased with! I can honestly say I didn’t feel hungry. I am diabetic and found that my blood sugar levels were stable throughout the trial. My friend has just asked me to be matron of honour at her wedding, so I’ll be back on the Almased plan soon!” Pauline Huckfield
6 | WWW.PRIMARYCAREREPORTS.CO.UK
Weight Loss and Improved Glycaemic Control An Almased®-supplemented diet not only regulates the feeling of satiety in the brain but can also increase the fat-burning process more effectively than a diet without Almased®. In 2005, a study first reported that diabetics could lose a significant amount of weight on 50 g of Almased® a day over six months8. The participants displayed significant improvements in fasting blood sugar, HbA1c and fasting insulin levels without making other lifestyle changes (Figure 5). A later trial in 2012 by the West German Diabetes and Health Centre further demonstrated that type 2 diabetics with severe insulin resistance – those receiving an average 150 IU of insulin per day – were able to halve their daily insulin requirement within weeks, simply by following an Almased® diet9. Crucially, these benefits were sustained over a long-term follow-up, and were greatest in participants receiving Almased®-only diets10, demonstrating that the results were specific and not merely a quick fix solution (Figure 6). However, this should be considered in the context that patients being treated with hypoglycaemic medications (insulin, glibenclamide, glimepiride, repaglinide) require appropriate pre-diet counselling, and potential medication adjustments11. In addition to its benefits in hunger and satiety regulation,
Almased® has three main research underpinnings for diabetics.
1. The glycemic index The Glycaemic Index (GI) ranks carbohydratecontaining foods according to their effects on blood glucose levels relative to pure glucose (the standard reference GI of 100) . Foods that are slowly absorbed have a low GI rating, while foods that are more quickly absorbed have a higher rating. Almased® therapy in the management of overweight people with diabetes is supported by a study from the Cochrane Collaboration, which concluded that a diet with a low glycemic index is superior to other diets13. In addition, a 2012 study showed that, after weight loss, energy expenditure was higher on a low-glycaemic index diet than on a low-fat diet14, especially when combined with exercise15.
2. Calorie restriction Our understanding of type 2 diabetes has been informed by the discovery that severe calorie restriction, associated with both bariatric surgery16,17 and VLCDs18 can effect clinical remissions in the disease. In the context of bariatric surgery for example, the effects on the blood sugar occur before substantial weight-loss occurs, with a similar effect following the use of VLCDs such as Almased®. Moreover, a recent study
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
FIGURE 5. THE EFFECTS OF ALMSED ON CRITICAL BLOOD PARAMETERS IN TYPE 2 DIABETES MELLITUS
Almased is More Effective in Reducing Metabolic Risk Factors than a Fat– Restricted Low Calorie Diet
reported complete remission following a VLCD in patients that had type 2 diabetes for 4 years19; in addition to normalized blood sugar levels, insulin production was increased to a normal level. Such low calorie proprietary diets are recommended by Diabetes UK20.
3. A protein-rich diet Although low-carbohydrate diets are associated with significant reductions in body weight and improvements in glycaemic control21, the main mechanism of action may simply be that energy intake is reduced by carbohydrate restriction22. However, it appears that altering the relative carbohydrate-to-protein ratio is equally important. Indeed, replacing carbohydrate with protein has been independently demonstrated to improve short-term glycemic control23. Furthermore, the Joslin Diabetes Center in the USA advocate diets that comprise approximately 40% carbohydrates, 30% fat, and 30% protein, which requires significantly more protein than previously thought necessary24.
Conclusions: Could Almased® Be the Perfect Fit For Weight Loss in Diabetes? In summary, Almased® provides reproducible and sustained weight loss in obese patients with and without type 2 diabetes, and has a
Scientific Reference
host of additional positive effects on the lipid profile, fatty liver, mood and more (Figure 1). Of note, Almased® has an extremely low glycaemic index of just 27, which is excellent for diabetics, overweight and obese patients that need to lose weight. Furthermore, any diet that follows the Almased® plan (Figure 2) provides a low calorie diet with macronutrient levels that are broadly consistent with the recommendations of both Diabetes UK and the Joslin Diabetes Centre. Importantly, its unique proprietary blend and preparation, which reduces both the appetite and insulin levels, offers benefits that go well beyond that of a typical meal replacement or diet aid.
König D, et al (2008). Effect of meal replacement on metabolic risk factors in overweight and obese subjects. Annals of Nutrition and Metabolism; 52(1):74-78. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 7
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
“We both started using Almased in September 2013.Our main intention was for weight loss, however my husband is a type 2 diabetic, so we really wanted to see
MR AND MRS BEAUTYMANN – BEFORE USING ALMASED
FIGURE 6. MEASURABLE LONG-TERM SUCCESS WITH ALMSED
whether it could also help him control his blood sugar levels. 8 months later we had collectively lost 9.5 stone; I lost 4 stone and my husband 5.5 stone. As a result his doctor has now taken him off one of his diabetic medications and overall we both look and feel healthier and energised. Almased really has changed our lives”. Carole Beautymann, Newcastle Upon Tyne
For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk 8 | WWW.PRIMARYCAREREPORTS.CO.UK
MR AND MRS BEAUTYMANN – AFTER USING ALMASED
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
References: 1
Reference to Almased research article “Scientific Research on Almased®” – see resources section of folder
2
Berg A et al. Using Almased in an Enriched Soya Diet for Weight Loss. German Journal of Sports Medicine, 2000, 51: 39.
3
D eibert P et al. Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soya-protein diet. International Journal of Obesity, 2004, Oct., 28 (10): 1349-52.
4
Dansinger ML et al. Comparison of the Atkins, Ornish, Weight Watchers and Zone Diets for weight loss and heart disease reduction. JAMA, 2005, 293: 43-53.
5
Berg A et al. Favorable metabolic properties of a soya-honey-yogurt product for meal replacement in overweight subjects with atherogenic risk. Atherosclerosis, 2008, 9: 253.
6
Deibert, P, König, D, Frey, I, and Berg, A. Effects of a meal replacement based on soya protein on hormonal and metabolic regulation in overweight and obese females. Obesity Reviews, 2010, 11, Suppl. 1, 240
7
König D et al. Fuel selection and appetite-regulating hormones after intake of a soya proteinbased meal replacement. Nutrition, 2012 Jan; 28(1): 35-9. Epub 2011 Jul 20.
8
Zänker KS, Erxleben-Neis J, Gottschalk G, Schweig N: Diabetes Typ 2 mellitus und Krebs. Deutsche Zeitschrift für Onkologie 2005; 37:114–121.
9
Kempf K, Schloot NC, Gärtner B et al (2013) Protein-rich meal replacement significantly reduces insulin demand, HbA1c and weight long-term in type 2 diabetes mellitus patients with >100 U insulin/day. J Hum Nutr Diet. DOI 10.1111/jhn.12145
10
Martin S, Gärtner B, Keil R, Kempf K (2013). Protein-rich meal replacement significantly reduces HbA1c, weight and antidiabetic medication in type 2 diabetes patients – a randomized controlled trial. Diabetes 62 (Suppl 1): 768-P
11
Stephan Martin. Scientific statement regarding the use of Almased for patients with type 2 diabetes. West-German Centre of Diabetes and Health, Catholic Hospital Group, Düsseldorf.
12
Diabetes UK. The Glycaemic Index (GI). http://www.diabetes.org.uk/Guide-to-diabetes/Managing-your-diabetes/Glycaemic-Index-GI/
13
Almased Improves Anthropometric Measures and Reduces Levels of Obesity
Thomas DE et al. Low glycaemic index or low glycaemic load diets for overweight and obesity. The Cochrane Library, 2007, Issue 3.
14
Ebbeling CB, Swain JF, Feldman HA, et al. (June 2012). Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA 307 (24): 2627–34. doi:10.1001/ jama.2012.6607.
15
Bray GA (June 2012). Diet and exercise for weight loss. JAMA 307 (24): 2641–2. doi:10.1001/jama.2012.7263.
16
Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008 Oct;51(10):1781-9. doi: 10.1007/s00125-008-1116-7. Epub 2008 Aug 26.
17
Sjöström L, et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004 Dec 23;351(26):2683-93
18
Diabetes UK. Very low calorie diets (VLCD) – a cure for diabetes? Available at: http://www.diabetes.org.uk/upload/dpc_speakers2013/wed/11.20_wed_dyson_aud.pdf
19
Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ et al. Reversal of type 2 diabetes: nor-malisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14.
20
Diabetes UK Nutrition working group. Evidence-Based Nutrition Guidelines for the Prevention and Management of Diabetes. May 2011. Diabetes Uk. Available at: http://www.diabetes.org.uk/Documents/Reports/nutritional-guidelines-2013-amendment-0413.pdf
21
Dyson P (2009). A review of low and reduced carbohydrate diets in weight loss in Type 2 diabetes. Journal of Human Nutrition and Dietetics 21; 550–538.
22
Bravata, D.M. et al (2003). Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 289 (14); 1837–50.
23
Gannon MC, Nuttall FQ (2004). Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with Type 2 diabetes. Diabetes; 53 (9): 2375–82.
24
Joslin Diabetes Center & Joslin Clinic. Clinical nutrition guideline for overweight and obese adults with type 2 diabetes, prediabetes or those at high risk of developing type 2 diabetes; 2007, 03, 29.
Scientific Reference König D, et al (2008). Effect of meal replacement on metabolic risk factors in overweight and obese subjects. Annals of Nutrition and Metabolism; 52(1):74-78 For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 9
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
The Central Role of the GP in the Obesity Epidemic Dr R A Sykes, Editor
Unsurprisingly then, obesity has become a major public health issue over the last decade as the political classes have caught up with the true scale of the burden
O
BESITY IS a major issue in our society, affecting nearly two thirds of the population1. In 2012, around 25% of adults in England were classified as obese (body mass index [BMI] 30 kg/m2 or more) and a further 42% of men and 32% of women were overweight (BMI 25 to 30 kg/m2)2. Levels of overweight and obesity among children are also high, with the disorder affecting a third of children aged 10–11 years and a quarter of those aged 4-5 years. Moreover, obesity is strongly correlated with social disadvantage as demonstrated in the Marmot Review, 20103, and is most prevalent among those with poor educational attainment4. Overall, the rates of obesity in the UK are amongst the highest of any developed country and represent a significant failure of public health policy. Although there is some evidence that the situation is stabilizing in children, the trends continue apace in adults.
The Cost to Society Unsurprisingly then, obesity has become a major public health issue over the last decade as the political classes have caught up with the true scale of the burden. Indeed, the realization of the financial cost to society was emphasized in the ‘Healthy Lives, Healthy People: A call to action on obesity in England’ document published in 20115. It reported that the estimated cost to society and the economy, of people being overweight or obese, was almost £16 billion in 2007 (more than 1% of gross domestic product), and that the cost to the National Health Service was £4.2 billion. Based on statistical modelling of trends over the last few decades, the overall costs to society and the NHS are expected to rise to just under £50 billion and £9.7 billion, respectively, by 2050 (based on 2007 prices).
Something Needs to Change Using a range of interventions designed both to prevent and to treat obesity, the government’s obesity strategy6 aims to see a downward trend in the level of excess weight in adults and a sustained downward trend in the level of excess 10 | WWW.PRIMARYCAREREPORTS.CO.UK
weight in children by 2020. In many areas, public, private or voluntary organisations have been commissioned to provide individual or group lifestyle weight management services and are encouraged to use commercial or voluntary programmes. However, there has been significant uncertainty about which weight management programmes are effective and constitute good value for money. To this end, documents such as the Loveman Report, 20117 offer the chance to refine and clarify best practice. What is clear, is the undoubted cost of neglecting to fund antiobesity strategies (£2.5 billion in some reports8), with cost-effectiveness estimates varying between £473 and £7200 (US$12,640) per quality-adjusted life-year gained7.
Enter Primary Care …. Primary care accounts for more than 90% of patient contact in the National Health Service, making it ideally placed to tackle obesity. Consequently, it has been targeted as the front line in the prevention and management of obesity. However, there are often insufficient resources and incentives, with The Action for Obesity Resources Campaign expressing serious concerns about the lack of focus on prevention and structured management in primary care9. Although weight management services continue to be a peripheral issue, monitoring obesity is now a requirement of the GMS contract10. Moreover, obesity is not only a clear component of several core indicators, such as coronary heart disease, diabetes, stroke, hypertension, and mental health – it attracts some 15 points in the 2013/14 contract (see Table 1). In addition, the National Institute for Health and Care Excellence (NICE) have created and built on comprehensive guidance that can be applied in primary care11. Of the eighteen core recommendations of the adult guidance, six are specifically targeted at general practitioners (see Table 2). Although several of the NICE guidelines are mundane, reflecting the mechanics of referral and management, they each contribute to a larger picture. With collaboration between agencies, full implementation could see major
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
TABLE 1. OBESITY INDICATORS IN THE 2013/14 GENERAL MEDICAL SERVICES (GMS) CONTRACT QUALITY AND OUTCOMES FRAMEWORK (QOF)1
Indicator
Points
Obesity (OB): Indicator – Records – OB001
The contractor establishes and maintains a register of patients aged 16 or over with a BMI ≥30 in the preceding 12 months
8
The register includes all patients whose BMI has been recorded in the practice as part of routine care. It is expected that this data will inform public health measures
Diabetes mellitus (DM): indicator DM013
The percentage of patients with diabetes, on the register, who have a record of a dietary review by a suitably competent professional in the preceding 12 months
3
Mental health: Indicator MH006
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 12 months
4
Almased Reduces Insulin Requirement in Type 2 Diabetics & Improves Lifelong Glycaemic Control
Legend: BMI, body mass index 2013/14 general medical services (GMS) contract quality and outcomes framework (QOF): Guidance for GMS contract 2013/14. Page 163 -164; Page 81 -83; and Page 120 -121. Available at: http://tiny.cc/gxn1mx
1
TABLE 2. THE RESPONSIBILITIES OF GENERAL PRACTITIONERS IN THE 2014 NICE GUIDELINES
Recommendation 2
Ensure services cause no harm
• Be aware of the effort needed to lose weight, prevent weight regain or avoid any further weight gain. Also, be aware of the stigma that adults who are overweight or obese may feel or experience. • Ensure equipment and facilities meet the needs of most adults who are overweight or obese. • Be aware that people may feel anxious about being weighed and measured. Recommendation 6
Refer overweight and obese adults to a lifestyle weight management programme
• Raise the issue of weight loss in a respectful and non-judgemental way. • Identify people eligible for referral to lifestyle weight management services by measuring their body mass index(BMI) and waist circumference (if BMI less than 35 kg/m2). • Provide information on locally available programmes. • Refer people to a group rather than an individual programme because these tend to be more cost effective. • Ensure people who are overweight or obese who are not referred (for whatever reason) can discuss and reconsider attending a programme in the future. Provide alternative sources of information. • Give people the opportunity for a re-referral, as necessary, because weight management is a long-term process. Recommendation 7 Address the expectations and information needs of adults thinking about joining a lifestyle weight management programme • Discuss the importance and wider benefits of making gradual, long-term changes to dietary habits and physical activity levels. • Discuss what the programme does and does not involve. • Discuss realistic weight-loss goals. i.e., the more weight they lose, the greater the health benefits, particularly if greater than 5% of their body weight and maintained for life, but stress that on average, people attending a lifestyle weight management programme lose around 3% of their body weight. • Discuss the effort and commitment needed to lose weight and prevent weight regain, and the benefit of receiving long-term support (e.g., practice nurse, pharmacist, local support group or weight management programme, online groups or networks, and friends or family). Recommendation 16 Improve information sharing on people who attend a lifestyle weight management programme • Commissioners of lifestyle weight management services should work with all referrers and providers to put systems in place to share any relevant information, in confidence, about people referred to lifestyle weight management programmes. This should be in line with the Department of Health’s information governance and data protection requirements (for example, see Public Health Services Contract 2014/15: guidance on the non-mandatory contract for public health services). • Referrers to, and providers of, lifestyle weight management programmes should seek the consent of participants to share relevant information. Recommendation 17
Monitor and evaluate programmes
• U se the standard evaluation framework for weight management programmes and validated tools to monitor interventions. • As a minimum, collect and assess the following data: o Weight (total and percent weight change). Do not rely on self-reported measures. o Percent of participants losing more than 3% of their baseline weight. o Percent of participants losing more than 5% of their baseline weight. o Percent adherence to the programme. o Age, gender, ethnicity and socioeconomic status (for example, postcode). • Consider collecting and assessing other outcomes, for example: o changes in other measures of body fatness, such as waist circumference o changes in dietary habits, physical activity and sedentary behaviour o changes in self-esteem, depression or anxiety o changes in health outcomes, such as blood pressure o the views and experience of participants who completed the programme o the views and experience of participants who did not complete the programme, and any changes in their weight o the views of staff delivering the programme and of those referring participants to it. Recommendation 11
(For service providers)
Provide lifestyle weight management programmes based on the core components for effective weight loss and to prevent weight regain
Scientific Reference Kempf K, et al (2014). Meal replacement reduces Insulin requirement, HbA1c and weight long-term in type 2 diabetes patients with >100 U insulin per day. Journal of Human Nutrition and Dietetics; 2:21-27 For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
roviders of lifestyle weight management programmes should ensure programmes are based on the core components P for effective weight loss, and should be designed to help prevent weight regain (see Recommendation 9 and Recommendation 10 in the NICE guidance). Legend: Abridged summary of the NICE guidance for the management of obesity in adults2. Abbreviations: NICE, National Institute of Health and Care Excellence. 2
http://tiny.cc/v0n1mx
WWW.PRIMARYCAREREPORTS.CO.UK | 11
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Whatever your perspective, there are clear financial, clinical and humanitarian reasons for exhausting all possible avenues of weight loss, regardless of how entrenched a patient’s position may be
FIGURE 1. PATIENT MOTIVATION: ARE THEY READY?1
If the patient is at the contemplation, action or maintenance atages of the cycle of change, they are suitable for a weight management intervention. It is a preferable to use a qualitative toll to assess if the patient is ready to use weight. The following tool is based on the work of Prochaska and Diclemente and has been used by the CounterWeight Programme. Questions to ask the patient (can be given in the form of a questionnaire before calling patients into the clinics). 1. In the past month, have you been actively trying to lose weight?
Y/N
2. In the past month, have you been actively trying to keep from gaining weight?
Y/N
3. Are you seriously considering trying to lose weight to reach your goal in the next 6 months?
Y/N
4. Have you maintained your desired weight for more than 6 months?
Y/N
Stage
Q1 Q2
Q3 Q4
Pre-contemplation
N
N
N These patients are not considering losing weight in the next 6 months. Discuss benefits of weight loss and risks of not changing. Reassess readiness to change at future appointments.
Contemplation
N
N
Y This group includes those patients who are seriously considering losing weight. Refer to treatment algorithm.
Action
Y on Q1 or Q2
N Patients who are actively trying to lose weight or who have been successful but for less than 6 months. reinforce all changes & encourage. Give additional support as required.
Maintenance
Y on Q1 or Q2
Y Patients who have successfully maintained their weight loss for at least 6 months. Reinforce all changes and encourage.
1 Figure taken from the Obesity Care Pathway Toolkit - annexes 1 to 9. The National Obesity Forum expert committee 2005. Available at: http://www.nationalobesityforum.org.uk/images/stories/care-pathway-toolkit/Toolkit_supporting_obesity_care_pathway_annexes_1_to_9__Feb_07_2006.pdf
benefits to the health and wellbeing of a typical practice population. At this point, it is worth noting that NICE recommend specific criteria for funded referrals. First, programmes are thought to offer most benefit for adults who are obese (a BMI over 30 kg/m 2); however, they add the important caveats that a lower threshold should apply for those from black and minority ethnic groups at higher risk, and for those with other risk factors such as type 2 diabetes and hypertension. Second, they recommend that where there is capacity, access should not be restricted for adults who are overweight (a BMI between 25 and 30 kg/m2.) Third, NICE recommend that there should be no upper BMI or upper age limit for referral. Although local policies vary, funded referrals to a lifestyle weight management programme (in tier 2 services) should last for around 12 weeks or 12 sessions.
The Call to Action All primary care providers should be aware of the core recommendations proffered by NICE, particularly the information in Table 2, and 12 | WWW.PRIMARYCAREREPORTS.CO.UK
should have policies in place to action those recommendations. Many of the recommendations not covered in Table 2 cover key issues for commissioners and service providers, and provide key guidance for service provision and commissioning. Those with an interest in these areas should refer to the NICE recommendations. The sheer weight of evidence that overweight and obesity continue to be major public health issues, and the unique position of primary care to tackle an issue with impact across the clinical spectrum, mandates increased attention and active efforts to stem the tide of growing waists and weights. Whatever your perspective, there are clear financial, clinical and humanitarian reasons for exhausting all possible avenues of weight loss, regardless of how entrenched a patient’s position may be. Indeed, simply moving a patient along on the next stage in the cycle of change represents a small victory for the general practitioner (Figure 1)12. For those patients who are ready to commit to change, the next article looks at some of the advances in our understanding of weight gain and maintenance, and the importance of a multicomponent strategy.
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
References: 1
Health Survey for England (2009), Health and lifestyles [NS]. NHS Information Centre, 2010. Available at: http://www.hscic.gov.uk/pubs/hse09report
2
Statistics on obesity, physical activity and diet: England 2014. Health and Social Care Information Centre 2014. Available at: http://www.hscic.gov.uk/catalogue/PUB13648
3
Fair society, healthy lives: strategic review of health inequalities in England post-2010, The Marmot Review 2010. Available at: http://www.instituteofhealthequity.org/projects/fair-society-healthy-lives-the-marmot-review
4
Statistics on obesity, physical activity and diet: England 2010. Health and Social Care Information Centre 2010. Available at: http://www.hscic.gov.uk/pubs/opad10
5
Healthy lives, healthy people: a call to action on obesity in England. Department of Health 2011.
Almased Positively Influences Hormones & Blood Parameters, Decreasing Chronic Disease Risk
Available at: https://www.gov.uk/government/publications/healthy-lives-healthy-people-a-call-to-action-on-obesity-in-england 6
Department of Health Policy: Reducing obesity and improving diet. Published 25 March 2013. Available at: https://www.gov.uk/government/policies/reducing-obesity-and-improving-diet
7
Loveman E1, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011 Jan;15(2):1-182. doi: 10.3310/ hta15020. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0015000/pdf/summ1502.pdf
8
Tackling Obesity in England. National Audit Office, 2001. Available at: http://www.nao.org.uk/report/tackling-obesity-in-england/
9
National Obesity Forum Sstatement on the General Medical Services Contract. National Obesity Forum, 2005. Available at: http://www.nationalobesityforum.org.uk/images/stories/Healthcare_Professionals/NOF_GMS_contract_backgrounder.pdf
10
2013/14 general medical services (GMS) contract quality and outcomes framework (QOF): Guidance for GMS contract 2013/14. Available at: http://tiny.cc/hr0zmx
11
12
NICE 2014 – Managing overweight and obesity in adults – lifestyle weight management services. Available at: https://www.nice.org.uk/guidance/PH53/chapter/1-recommendations OBESITY CARE PATHWAY TOOLKIT - Annexes 1 to 9. The National Obesity Forum EXPERT COMMITTEE 2005. Available at: http://tiny.cc/3s0zmx
Scientific Reference Zanker K, et al (2005). Type 2 Diabetes Mellitus and Cancer - a Nutritionoriented Intervention Study. German Journal of Oncology; 37: 114-121 For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 13
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
The Importance of Modest Weight Loss and a Multicomponent Diet Programme Susan Thomas, Medical Correspondent
Relying on medical approaches, and neglecting the essential input of dietary intervention that seeks to restrict calorie intake, is naïve at best
T
HERE IS a clear link between increasing body weight – both overweight and obesity – and significant medical comorbidity. Notably, this includes the risk of hypertension (4-fold for women; 2.5-fold for men), as well as heart attacks, angina, colon cancer, gall bladder disease, liver disease, ovarian cancer, osteoarthritis and stroke1. Interestingly, there is also evidence that both survival and recurrence after cancer may be adversely affected by obesity2. However, perhaps the strongest link is that between obesity and type 2 diabetes, with obesity significantly increasing the risk of developing the condition (13-fold for women; 5-fold for men)1. Figure 2 summarizes the proportions of disease prevalence that is thought to be due to obesity, and makes grim reading. Moreover, clear lessons can be learnt from the associations between body weight, body weight control and the metabolic consequences of type 2 diabetes3.
Any Weight Loss Is Good, but It Only Needs To Be Modest Being overweight is bad for you; most clinicians can accept that as fact. The opposite, that weight loss is good for you, holds true both acutely and during sustained weight loss. During acute weight loss, you enter a state of negative energy balance that improves glycemic control and reduces low-density lipoprotein, high-density lipoprotein, triglyceride, C-reactive protein and blood pressure levels. With sustained weight loss, you can then expect to see the high-density lipoprotein level rise. However, what most people fail to realise is that an initial loss of 5%-10% of body weight from baseline – that is, modest weight loss – is sufficient to achieve these metabolic benefits4. At modest levels, weight loss has been found to be preventive. The famous Diabetes Prevention Program (DPP)5, with 11 cases of diabetes per 100 people with impaired glucose tolerance, found 14 | WWW.PRIMARYCAREREPORTS.CO.UK
that a modest 7% weight loss was associated with a 58% reduction in the conversion to type 2 diabetes. Equally, the 1-year Look AHEAD (Action For Health in Diabetes) study6 reported that 68.0% of participants who received intensive lifestyle counseling had lost 5% of their initial body weight after 1 year compared with 13.3% of participants who received usual care, increasing to 50.3% and 35.7%, respectively, at 8 years. Moreover, the 5% weight loss resulted in significant improvements in type 2 diabetes, sleep apnea, depression, and physical functioning; specifically, an 8.6% weight loss at 1 year significantly improved glycemic control. Crucially, the DPP also found little increased benefit with weight loss beyond 10% from baseline5. The proposed mechanism is that, if you can achieve a 10% weight loss, you actually shrink your visceral adipose depots by about 30%7. Thus, metabolically active fat is disproportionately reduced at this weight loss level, which improves insulin sensitivity, blood insulin levels and blood glucose levels, and also reduces the risk factors for thrombosis, lowers inflammatory markers and improves endothelial function.
Obesity Has a MultiDimensional Pathogenesis Humans have evolved a myriad of interacting systems with multiple redundancies to help us cope with food scarce environments where we were at equal risk from famine and predators8. Figure 3 broadly summarizes what continues to be our primary biological control of fuel metabolism; it neatly summarizes that no one signal controls appetite, food intake and body weight, but that multiple signals combine to do so. Even by itself, such a model remains highly onedimensional, as energy balance is much more complicated. Figure 48 adds to the first image, demonstrating that there are a host of factors that modify dietary control.
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
FIGURE 2. PROPORTION OF DISEASE PREVALENCE ATTRIBUTABLE TO OBESITY2
Almased Enhances Mood, Cognitive Well–being and Overall Quality of Life
FIGURE 3. PERIPHERAL AND CENTRAL SIGNALS IN THE REGULATION OF FOOD INTAKE, WEIGHT AND METABOLISM
Scientific Reference Key signals drive from (1) central neural pathways (neuropeptides, lipids and transmitters) (2) the gut (GLP-1, GIP, PYY), and (3) the pancreas (glucagon, insulin, and amylin)3
An interesting area of current research into weight control is the highly refined corticolimbic system and the roles of learning, memory and reward circuits (Figure 4). According to Professor John Blundell of the University of Leeds9, there is increasing evidence of what appears to constitute food addiction. Over the last decade or so, you may have seen increasing numbers of articles referring to sugar addiction10 and food addiction9, or to the notion that fat creates addiction-like reward dysfunction and compulsive overeating through dopaminergic systems11. In such cases, food addiction is about hedonic rather than homeostatic control of eating12, with differing levels of food preoccupation, loss of control, and positiveoutcome expectancy13.
Treatment Approaches Must Evolve Our current understanding of the research base suggests that targeting any one signal for hunger, appetite, satiety or food addition might be inadequate. This is because we have evolved many redundant systems to ensure adequate calorie and nutrient intakes (see Figures 3 and 4). Indeed, it seems clear that the full satiety response is mediated through a series of gut and central signals, with some patients probably having a hedonically driven food addiction. Therefore, targeting the multiple and redundant systems may well be needed to achieve and sustain weight loss. Perhaps we should take lessons from the management of other diseases with complex pathophysiologies, such as diabetes and
Berg A, et al (2011). Meal replacement based on soy protein improves benefits of a weight reduction program on health related quality of life (HRQOL) in middle-aged obese females. Poster presented at the 18th European Congress on Obesity (ECO) 25th-28th May 2011. Istanbul. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 15
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Although improved
FIGURE 4. SCHEMA OF THE FACTORS INVOLVED IN ENERGY BALANCE, REGULATION AND CONTROL OF FOOD INTAKE
drug therapies clearly have an important role to play, they are insufficient when used in isolation Highly schematic diagram showing the major components and flow of information in the peripheral and central systems involved in energy balance, regulation and control of food intake4
hypertension, where combination approaches are needed to tackle different pathways. In this arena, candidate targets for regulating body weight include catecholamines (phentermine), serotonin and norepinephrine (sibutramine), serotonin (fenfluramine), endocannabinoids (rimonabant, taranabant), and selective serotonin 2c receptor agonists (lorcaserin), as well as drugs to control hedonically driven overconsumption (e.g., naltrexone and naloxone)14.
Treatment Should Focus On the Multidimensional Nature of Obesity Although improved drug therapies clearly have an important role to play, they are insufficient when used in isolation. Indeed, in 2011, Loveman et al. found that long-term multicomponent weight management interventions were generally the most effective means of promoting weight loss in overweight or obese adults15. Importantly, they
16 | WWW.PRIMARYCAREREPORTS.CO.UK
concluded that weight management interventions were cost-effective in the context of healthcare, with the caveat that several of the included studies had methodological issues. So, what we need is a multicomponent approach with the judicial use of one or more medications14, with or without exercise programmes16, meal replacements and low calorie diets17, cognitive and behavioural therapy18, and bariatric surgery19. For any efforts to be truly costeffective, what is certain is that the sort of lasting lifestyle changes that require active input by the patient must occur. To this end, relying on medical approaches, and neglecting the essential input of dietary intervention that seeks to restrict calorie intake, is na誰ve at best. Moreover, asking patients to meet and maintain unrealistic weight targets may be unnecessary, with significant benefits being gained from modest weight losses of 5%10%7. It now appears clear that such levels can be achieved by targeted, multicomponent weight management programmes.
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
References: 1
Statistics on obesity, physical activity and diet: England, 2011, NHS Information Centre, 2011. Available at: www.nao.org.uk/ publications/0001/tackling_obesity_in_england.aspx
2
Department of Health. Corporate report: Our health and well-being today. Available at: https://www.gov.uk/government/publications/our-health-and-well-being-today.
3
Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427-434. Available at: http://www.nejm.org/doi/full/10.1056/NEJM199908053410607
4
2013/14 general medical services (GMS) contract quality and outcomes framework (QOF): Guidance for GMS contract 2013/14. http://tiny.cc/5t5zmx
5
Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. Nov 14, 2009; 374(9702): 1677–1686. doi: 10.1016/S0140-6736(09)61457-4. Available at: http://europepmc.org/articles/PMC3135022
6
Thomas A. Wadden, Ph.D., Rebecca H. Neiberg, M.S., and the Look AHEAD Research Group. Four-Year Weight Losses in the Look AHEAD Study: Factors Associated with Long-Term Success. Obesity (Silver Spring). Oct 2011; 19(10):1987-1998. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183129/
7
Després J-P, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716–720. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1119905/
8
Natalie R. Lenard, Hans-Rudolf Berthoud. Central and Peripheral Regulation of Food Intake and Physical Activity: Pathways and Genes. Obesity (Silver Spring). Dec 2008; 16(Suppl 3): S11–S22. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687326/
9
J. Blundell, S. Coe, and B. Hooper. Conference Report: Food addiction – What is the evidence? Nutrition Bulletin, Volume 39, Issue 2, pages 218–222, June 2014. doi: 10.1111/nbu.12092. Available at: http://tiny.cc/bw5zmx
10
Avena, N.M., Rada, P., Hoebel B.G., 2007. Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. Neuroscience and Biobehavioral Reviews Volume 32, Issue 1, 2008, Pages 20–39
11
Paul M Johnson, Paul J Kenny. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nature Neuroscience 13, 635–641 (2010) doi:10.1038/nn.2519
12
Saper CB, Chou TC, Elmquist JK. The need to feed: homeostatic and hedonic control of eating. Neuron, 2002;36:199–211.
13
Fairbun CG, Beglin, S. The EDE-Q 6.0 (Eating Disorder Examination Questionnaire). Appendix in Fairburn C.G. Cognitive Behaviour Therapy and Eating Disorders. Guilford Press, New York, 2008. http://www.rcpsych.ac.uk/pdf/EDE-Q.pdf
14
Vojtech Hainer and Irena Aldhoon Hainerová. Do we need anti-obesity drugs? Volume 28, Issue Supplement s2, pages 8–20, December 2012 http://onlinelibrary.wiley.com/doi/10.1002/dmrr.2349/full
15
Loveman E, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011 Jan;15(2):1-182. doi: 10.3310/hta15020.
16
T. Wu, X. Gao, M. Chen and R. M. Van Dam. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obesity Reviews; Volume 10, Issue 3, pages 313–323, May 2009. DOI: 10.1111/j.1467-789X.2008.00547.x. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1467-789X.2008.00547.x/full
17
Adam Gilden Tsai andThomas A. Wadden. The Evolution of Very-Low-Calorie Diets: An Update and Meta-analysis. Obesity; Volume 14, Issue 8, pages 1283–1293, August 2006. DOI: 10.1038/ oby.2006.146. Available at: http://onlinelibrary.wiley.com/doi/10.1038/oby.2006.146/full
18
Silja Vocks, Brunna Tuschen-Caffier, Reinhard Pietrowsky, Stephan Jeff Rustenbach, Anette Kersting and Stephan Herpertz. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. International Journal of Eating Disorders. Volume 43, Issue 3, pages 205–217, April 2010. DOI: 10.1002/eat.20696. Available at: http://onlinelibrary.wiley.com/doi/10.1002/eat.20696/abstract
19
L Sjöström. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. International Journal of Obesity (2008) 32, S93–S97; doi:10.1038/ijo.2008.244. Available at: http://www.nature.com/ijo/journal/v32/n7s/full/ijo2008244a.html
Almased Controls Appetite– Regulating Hormones, Promoting Greater Fat Oxidation
Scientific Reference König D, et al (2012). Fuel selection and appetite-regulating hormones after intake of a soy proteinbased meal replacement. Nutrition; 28:35-39. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 17
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
The Role of Low Calorie Diets as Part of Weight Loss Programmes G A Hood
Importantly, as reported in the influential Look AHEAD study, although greater self-reported physical activity was the strongest correlate of weight loss, it was followed closely by treatment attendance and consumption of meal replacements
To achieve weight loss, we all know that patients must enter an energy deficient state. Put simply, net energy expenditure (exercise) must be greater than net energy consumption (food): you must take in less than you use to force your body to consume fat stores. One of the most potent means of achieving this is by consuming low calorie diets1, either by specifying a target energy intake (e.g., 1200 -1500 kcal/day for women and 1500-1800 kcal/day for men) or by estimating individual energy requirements and prescribing an energy deficit (e.g., 500 kcal/day). Another approach is to recommend that certain foods be restricted or eliminated, or to prescribe meal replacements with or without calorie targets. In the context of reduced energy intake, it is clear that a host of different diets can produce effective weight loss. Common themes are the reduction of macronutrient levels, specifically fat and carbohydrate levels, and the increase of foods that have a low glycaemic index and are protein rich. However, the most important factor is the commitment to intensive multidisciplinary support, including behavioral or counseling components. Here we consider some of the macronutrientbased calorie deficient diets, and briefly assess their relative merits
Low-Fat Diets Since the 1980s an evidence base emerged for the efficacy of lower fat diets for chronic disease risk reduction, with expert guidelines continuing to advocate their adoption for disease prevention and health promotion2,3. This was also plausible given the energy dense nature of fat (9 kcal/g compared to 4 kcal/g for protein and carbohydrate). In overweight and obese adults, when calorie-restricted (500–750 kcal deficit per day) low fat (<30% of total calories from fat) and high fat (>40 percent of total calories from fat) diets are compared the results are comparable4,5. However, with moderate weight loss, low fat diets produce greater reductions in LDL-C and
18 | WWW.PRIMARYCAREREPORTS.CO.UK
triglyceride levels, and lesser increases in HDL-C. A widely accepted negative is that the satiety and palatability of lower fat or fat-free foods can be poor, often lacking the hedonic attributes of fatcontaining foods.
High Protein Diets Physiological and clinical studies have demonstrated that dietary protein promotes satiety and increases resting energy expenditure6,7 to improve weight loss. Trials have tested this hypothesis by prescribing an energy deficit diet with targets to increase protein to 25%30% percent of total calories8,9 or by providing foods that meet those targets10,11. Using the first approach, many studies failed to reach the macronutrient targets for protein and found no differences in weight loss between groups by protein intake. Unfortunately, the authors concluded that, in real-world settings, advising patients to increase protein consumption without a prescribed meal replacement was difficult to achieve due to the wide availability of palatable foods that are low in protein and high in fat and carbohydrate. The second approach has had mixed results in increasing dietary protein and reducing glycemic load, with one study finding no significant differences in weight loss between groups in a metabolic ward setting11 and another, where dieticians instructed participants to select foods with appropriate macronutrient content, having good success10.
Low Carbohydrate and Low Glycaemic Index Diets Low-carbohydrate diets such as the Atkins Diet12 have been popular for many decades, due in part to the rapid initial weight loss that occurs through glycogen depletion. Studies suggest that consuming a carbohydraterestricted diet (20 g/day for up to 3 months) can sustain increased weight loss for 1-3 months, but that no differences in weight loss persist
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
TABLE 3. METABOLIC PARAMETERS BEFORE AND AFTER THE IPM INTERVENTION
Variables
Pre-intervention
Post-intervention
Body weight (kg)
103.2 ± 11.8
97.0 ± 11.8***
BMI (kg/m2)
35.0 ± 3.9
33.0 ± 4.0***
Waist circumference (cm)
113.9 ± 10.4
108.4 ± 9.6**
Triglycerides (mg/dl)
328 ± 241
175 ± 79**
HDL cholesterol (mg/dl)
45.8 ± 12.8
45.2 ± 10.4
LDL cholesterol (mg/dl)
149 ± 44.1
126 ± 53.5*
Fasting blood glucose (mg/dl)
131± 37
105 ± 14**
Haemoglobin A1c (%)
6.7 ± 0.7
6.3 ± 0.7***
Almased Reduces Body Fat Mass & Lowers LDL Cholesterol & Triglyceride Levels
Legend: The pre-diabetic and pre-atherosclerotic phenotype in the subgroup of patients with metabolic syndrome _ SD; pre-post-significances given as p<0.05 (*), or type 2 diabetes before and after 6 weeks of intervention. n = 12; mean + p<0.01(**), p<0.005(***). Abbreviations: BMI, body mass index; LDL, low density lipoprotein; HDL, high density lipoprotein
FIGURE 5. COMPONENTS OF ALMASED® USED IN THE IPM CONCEPT WITH ITS POSTULATED HEALTH BENEFITS
Scientific Reference by 6 months when compared with low-fat diets 13,14. However, diets that manipulate glycemic index have also become popular, particularly for diabetes and pre-diabetes weight loss, because they attempt to modify insulin secretion. Low-glycemic load foods tend to be higher in fiber and have higher levels of complex carbohydrates and lower levels of simple carbohydrates, which produce a moderated insulin response and less hunger in the long term. Although the low-glycemic index approach is popular in patients with diabetes and prediabetes, and clearly contributes to significant weight loss over 6 months, weight loss is comparable to that on other diets15. That said, there is some evidence that patients on low glycaemic index diets can lose a mean of 1 kg more than those on comparison diets, with lipid profiles also improving16.
Meal Replacements, Liquid Diets and Very Low-Calorie Diets Meal replacements are commercial, portioncontrolled products that are typically used to enforce caloric restraint. Importantly, as reported in the influential Look AHEAD study, although greater self-reported physical activity was the strongest correlate of weight loss, it was followed closely by treatment attendance and consumption of meal replacements17. Comparing dietitian-led counseling with and without the use of liquid or bar meal replacements , the use of meal replacements in overweight and obese women has been clearly associated with increased weight loss at 6 months when compared with a balanced calorie deficient diet utilizing conventional food17,18. Additionally, longterm (<1 year) weight loss with very low calorie diets (VLCDs) is not typically different from that
Berg A, et al (2013). Benefits of a short-time intervention concept for weight reduction and improvement of the metabolic milieu in overweight adults. Presented at the 6th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 27th February-2nd March. Paris, France. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 19
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Most authorities recommend that clinicians should prescribe a diet to achieve reduced calorie intake for obese or overweight individuals as part of a comprehensive lifestyle intervention
THE IDEAL MEAL REPLACEMENT The IPM Method – A Low Calorie, Low Protein, Low-GI Meal Replacement Based on much of this research, the Freiburg Institute of Preventive Medicine (IPM) conducted an interesting study using a proprietary low-glycemic protein-rich isoflavone-rich meal replacement22. In total, they enrolled 48 patients and provided an initial consultation to discuss energy balance and therapeutic life style changes. Subsequently, the participants received a clinically approved, low-glycemic meal replacement (Almased®, 1 g per kg normal weight twice a day). Among the 40 patients who completed the programme, significant results were seen in terms of weight loss and metabolic parameters (Table 3); notably, all completers lost weight (females -5.3%, males -5.6%) and had significant metabolic improvements. The IPM concept proved to be a successful way to lose weight and improve the metabolic milieu associated with obesity in a short period. Moreover, it generated demonstrable health benefits after 6 weeks of intervention, even among a subgroup of patients with impaired glucose tolerance. The authors argue that the soy-based (protein-rich) product showed not only a calorie-sparing effect but may also have provided potential health benefits23, including reduced body fat, reduced hepatic fat, improved fatty acid metabolism (lowered plasma LDL-cholesterol and triglyceride levels), and decreased insulin resistance24,25, (Figure 5). In addition, health-related quality of life may be enhanced by the use of this weight reduction programme26.
of other low-calorie diets, but they are noted for their superiority in achieving more rapid initial weight losses19. This is particularly the case for protein-based meal replacements (30 g protein/day)20. Put simply, high protein meal replacements appear to provide the best weight loss option.
Recommended Dietary Strategies for Weight Loss Most authorities recommend that clinicians should prescribe a diet to achieve reduced calorie intake for obese or overweight individuals as part of a comprehensive lifestyle intervention. This can
20 | WWW.PRIMARYCAREREPORTS.CO.UK
include calorie restriction alone, or the prescription of an evidence-based diet that restricts certain food types to create an energy deficit. But remember, if a diet does not appear to work, then there must be excessive calorie consumption relative to energy expenditure, and you should consider re-addressing patient eduction and motivation. If no issue exists with either of these, it may be that the selected diet was unsuitable for that patient. In this context, a different approach should be trialled. Although many options are available, the success of the IPM method suggests that products like Almased® should be high on your list of alternatives.
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
References: ( 2014), Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity, 22: S41–S410. doi: 10.1002/oby.20660. Available at: http://onlinelibrary.wiley.com/doi/10.1002/oby.20660/full 2 American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee.Circulation. 2006;114(1):82-96. 3 American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31 Suppl 1:S61-78. Erratum in: Diabetes Care. 2010;33(8):1911. 4 Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007;297(19):2092-102. 5 Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weightloss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-73. 6 Halton TL, Hu FB. The effects of high protein diets on thermogenesis, satiety and weight loss: a critical review. J Am Coll Nutr. 2004;23(5):373-85. 7 Lejeune MP, Westerterp KR, Adam TC, Luscombe-Marsh ND, Westerterp-Plantenga MS. Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber. Am J Clin Nutr. 2006;83(1):89-94. 8 Frisch S, Zittermann A, Berthold HK, Götting C, Kuhn J, Kleesiek K, et al. A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program. Cardiovasc Diabetol. 2009;8:36. 9 Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weightloss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-73. 10 Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord. 2004;28(10):1283-90. 11 Pittas AG, Roberts SB, Das SK, Gilhooly CH, Saltzman E, Golden J, et al. The effects of the dietary glycemic load on type 2 diabetes risk factors during weight loss. Obesity (Silver Spring). 2006;14(12):2200-9. 12 Atkins R. Dr. Atkins’ NEW diet revolution. New York: HarperCollins; 2002 13 Foster GD, Wyatt HR, Hill JO, Makris AP, Rosenbaum DL, Brill C, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010;153(3):147-57. 14 McAuley KA, Hopkins CM, Smith KJ, McLay RT, Williams SM, Taylor RW, et al. Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia. 2005;48(1):8-16. 15 Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007;297(19):2092-102. 16 Diana Thomas, Elizabeth J Elliott, Louise Baur. Low glycaemic index or low glycaemic load diets for overweight and obesity. The Cochrane Library. DOI: 10.1002/14651858.CD005105.pub2. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005105.pub2/abstract 17 Wadden et al. The Look AHEAD Research Group. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009 Apr;17(4):713-22. doi: 10.1038/oby.2008.637. Epub 2009 Jan 29. 18 Ashley JM, St Jeor ST, Perumean-Chaney S, Schrage J, Bovee V. Meal replacements in weight intervention. Obes Res. 2001;9 Suppl 4:312S-20S. 19 National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults – The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S 20 Lejeune MPGM, Kovacs EMR, Westerterp-Plantenga MS. Additional protein intake limits weight regain after weight loss in humans. Br J Nutr. 2005;93(2):281-9. 21 Berg A, Schaffner D, Stensitzky A, Deibert P, König D. Benefits of a short-time intervention concept for weight reduction and improvement of the metabolic milieu in overweight adults. Institut für Präventive Medizin (IPM®), Freiburg, Germany. Presented at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Paris, February 27th – March 2nd, 2013 22 Deibert P, König D, Schmidt-Trucksaess A, Zaenker KS, Frey I, Landmann U, Berg A. Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet. Int J Obes Relat Metab Disord. 2004; 28:1349 23 Gonzalez de Mejia E, Vásconez M, de Lumen BO, Nelson R. Lunasin concen-tration in different soybean genotypes, commercial soy protein, and isoflavone products. J Agric Food Chem. 2004; 52:5882 24 Hamden K, Jaouadi B, Carreau S, Aouidet A, Elfeki A. Therapeutic effects of soy isoflavones on a-amylase activity, insulin deficiency, liver-kidney function and metabolic disorders in diabetic rats. Nat Prod Res. 2011; 25:244 25 Velasquez MT, Bhathena SJ. Role of dietary soy protein in obesity. Int J Med Sci. 2007; 26:72 26 Sadaf Koohkan et al. The impact of a weight reduction program with and without mealreplacement on health related quality of life in middle-aged obese females. BMC Women’s Health 2014, 14:45. Available at: http://www.biomedcentral.com/1472-6874/14/45 1
Almased Retains Muscle Mass While Burning Fat & Losing Weight
Scientific Reference Deibert P, et al (2004). Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soya-protein diet. International Journal of Obesity: 28 (10); 1349-52. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 21
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Weight Loss: A Summary of Where We Are Dr R A Sykes, Editor
Perhaps the most important take home message is that meal replacements work for weight loss in both diabetes and other patient groups, and are strongly advocated by expert opinion. As reported in the Look AHEAD study, physical activity, treatment attendance and the use of meal replacements correlate most strongly with weight loss
22 | WWW.PRIMARYCAREREPORTS.CO.UK
This report has covered some of the key advances in our understanding of weight loss in the management of overweight or obese patients in primary care settings. It is clear that obesity continues to represent a significant public health issue, and that although some trends are stabilizing, it remains far too early to make any meaningful judgement on whether existing strategies are adequate to meet the demands. Indeed, the demands are legion: being overweight or obese has significant impacts on both the individual and wider society, from personal morbidity and mortality, to lost productivity and growing costs for an already stretched health service. Consequently, service providers and commissioners must continue to play a key role in stemming the tide over coming decades. All primary care providers in the UK should be aware of the core recommendations proffered by National Institute of Health and Care Excellence (NICE)1,2 (Table 2) and should have policies in place to action those recommendations, not least because of the clear financial, clinical and humanitarian reasons for exhausting all possible avenues of weight loss. However, it is clear that doing so will be difficult. In this final article, I seek to bring together some of the key lessons from this report and look to the future needs incumbent on all of us with a vested interest in this topic.
as necessary. Moreover, it appears that asking patients to meet and maintain unrealistic target weights may be unnecessary, with significant health benefits gained from modest weight losses of 5%–10%10,11. One of the most potent means of achieving weight loss is by consuming low calorie diets, either with target energy intakes (e.g.,1200– 1500 kcal/day for women and 1500-1800 kcal/ day for men) or with prescribed energy deficits (e.g., 500 kcal/day). Although a host of low fat (<30% of total calories from fat)12,13, high protein (25%–30% of total calories)14,15,16,17, low carbohydrate18,19, and low glycaemic index diets have comparable weight loss effects, each produces effective weight loss with specific benefits in different clinical populations. However, perhaps the most important take home message is that meal replacements work for weight loss in both diabetes and other patient groups, and are strongly advocated by expert opinion. As reported in the Look AHEAD study, physical activity, treatment attendance and the use of meal replacements correlate most strongly with weight loss20. Moreover, meal replacements that have a low glycaemic index and low protein content appear to offer the best short to medium term results, notably improving satiety and reducing hunger.
What is Known?
Most authorities with an interest in the control of obesity, diabetes, heart disease and weight loss recommend that clinicians should prescribe a diet to achieve reduced calorie intake for obese or overweight individuals as part of a comprehensive lifestyle intervention. Delivering these programmes in the context of a poorly funded NHS can be challenging at best. Position papers such as ‘Healthy Lives, Healthy People: A call to action on obesity in England’21 and the updated NICE guidelines for obesity1 and diabetes2 go some way to address these needs. In addition, the General Medical Services (GMS) contract22 seeks to incentivise management. But, efforts remain inadequate.
Overweight and obesity continue to be major public health issues, and the unique position of primary care necessitates its active involvement. Although drug therapies clearly have an important role to play, long-term multicomponent weight management interventions appear to be most effective in promoting weight loss in overweight or obese adults3, and appear cost-effective (between £473 and £7200 per quality-adjusted life-year gained). Such an approach should employ the judicial use of one or more medications4 with or without exercise programmes5, meal replacements6, cognitive and behavioural therapy7,8, and bariatric surgery9
What Next?
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
Although the GMS contract now includes a specific obesity measure and provides more points for weight loss in other conditions, it still fails to incentivise weight loss targets for obesity as aggressively as the scale of the problem merits. In addition, the NICE guidelines fail to recognise the importance of meal replacements that target weight loss in diabetics, despite evidence that standard interventions can be inadequate and inferior to meal replacement options10. Moreover, they often discourage the use of foods marketed specifically for people with diabetes2. Given the evidence for the increased effectiveness of meal replacements and for the ability of diet to reverse the metabolic sequelae of obesity9,10,23, it is perhaps time that the role of prescribed meal replacements gains greater mainstream attention. Finally, more needs to be done in terms of health protection. A policy update on reducing obesity and improving diet was published in March 2013 by the Department of Health, with four areas of action24: giving advice on a healthy diet
and physical activity through the ‘Change4Life’ programme25; improving labelling on food and drink to help people make healthy choices with a consistent front of pack labelling system26; encouraging businesses on the high street to include calorie information on their menus through the Public Health Responsibility Deal27; and providing guidance on physical activity levels28. However, although clearly a step in the right direction, uptake has been sporadic and it is premature to assess the beneficial effects of this guidance.
Almased Reduces Metabolic Syndrome & Cardiovascular Risk Factors
Conclusions The overabundance of palatable food in our society that is high in fat and low in protein encourages hedonic consumption29. In tandem with increasingly sedentary lifestyles, it is unsurprising that many weight loss programmes fail. Ultimately, weight loss is the responsibility of the patient, but health care providers, commissioners, government and industry all have roles to play.
Scientific Reference Deibert P, et al (2007). Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutrition Journal 6; 31: 1-7. For more information: please call 020 7969 1886 or email info@almased.co.uk or visit almased.co.uk
WWW.PRIMARYCAREREPORTS.CO.UK | 23
SPECIAL REPORT: THE ROLE OF ADVANCED MEAL REPLACEMENTS IN WEIGHT LOSS PROGRAMMES
References: 1
NICE 2014- Managing overweight and obesity in adults – lifestyle weight management services. Available at: https://www.nice.org.uk/guidance/PH53/chapter/1-recommendations
2
NICE 2014 update – diabetes. Source: http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf
3
Loveman E1, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of longterm weight management schemes for adults: a systematic review. Health Technol Assess. 2011 Jan;15(2):1-182. doi: 10.3310/hta15020.
4
Vojtech Hainer and Irena Aldhoon Hainerová. Do we need anti-obesity drugs? Volume 28, Issue Supplement s2, pages 8–20, December 2012 http://onlinelibrary.wiley.com/doi/10.1002/dmrr.2349/full
5
T. Wu, X. Gao, M. Chen and R. M. Van Dam. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obesity Reviews; Volume 10, Issue 3, pages 313–323, May 2009. DOI: 10.1111/j.1467-789X.2008.00547.x. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1467-789X.2008.00547.x/full
6
Adam Gilden Tsai andThomas A. Wadden. The Evolution of Very-Low-Calorie Diets: An Update and Meta-analysis. Obesity; Volume 14, Issue 8, pages 1283–1293, August 2006. DOI: 10.1038/oby.2006.146. Available at: http://onlinelibrary.wiley.com/doi/10.1038/oby.2006.146/full
7
Fairbun CG, Beglin, S. The EDE-Q 6.0 (Eating Disorder Examination Questionnaire). Appendix in Fairburn C.G. Cognitive Behaviour Therapy and Eating Disorders. Guilford Press, New York, 2008. http://www.rcpsych.ac.uk/pdf/EDE-Q.pdf
8
Silja Vocks, Brunna Tuschen-Caffier, Reinhard Pietrowsky, Stephan Jeff Rustenbach, Anette Kersting and Stephan Herpertz. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. International Journal of Eating Disorders. Volume 43, Issue 3, pages 205–217, April 2010. DOI: 10.1002/eat.20696. Available at: http://onlinelibrary.wiley.com/doi/10.1002/eat.20696/abstract
9
L Sjöström. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. International Journal of Obesity (2008) 32, S93–S97; doi:10.1038/ijo.2008.244. Available at: http://www.nature.com/ijo/journal/v32/n7s/full/ijo2008244a.html
10
Thomas A. Wadden, Ph.D., Rebecca H. Neiberg, M.S., and the Look AHEAD Research Group. Four-Year Weight Losses in the Look AHEAD Study: Factors Associated with Long-Term Success. Obesity (Silver Spring). Oct 2011; 19(10):1987-1998. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183129/
11
Després J-P, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716–720. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1119905/
12
Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007;297(19):2092-102.
13
Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-73.
14
Frisch S, Zittermann A, Berthold HK, Götting C, Kuhn J, Kleesiek K, et al. A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program. Cardiovasc Diabetol. 2009;8:36.
15
Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-73.
16
Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord. 2004;28(10):1283-90.
17
Pittas AG, Roberts SB, Das SK, Gilhooly CH, Saltzman E, Golden J, et al. The effects of the dietary glycemic load on type 2 diabetes risk factors during weight loss. Obesity (Silver Spring). 2006;14(12):2200-9.
18
Foster GD, Wyatt HR, Hill JO, Makris AP, Rosenbaum DL, Brill C, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010;153(3):147-57.
19
McAuley KA, Hopkins CM, Smith KJ, McLay RT, Williams SM, Taylor RW, et al. Comparison of high-fat and high-protein diets with a highcarbohydrate diet in insulin-resistant obese women. Diabetologia. 2005;48(1):8-16.
20
Wadden et al. The Look AHEAD Research Group. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009 Apr;17(4):713-22. doi: 10.1038/oby.2008.637. Epub 2009 Jan 29.
21
Department of Health. Policy paper - Healthy Lives, Healthy People: A Call to Action on Obesity in England, 2011. Published 13 October 2011. Available at: https://www.gov.uk/government/publications/healthy-lives-healthy-people-a-call-to-action-on-obesity-in-england
22
2013/14 general medical services (GMS) contract quality and outcomes framework (QOF): Guidance for GMS contract 2013/14. Available at: http://tiny.cc/1s8zmx
23
Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ et al. Reversal of type 2 diabetes: nor-malisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14.
24
Department of Health. Policy: Reducing obesity and improving diet. Published 25 March 2013. Available at: https://www.gov.uk/government/policies/reducing-obesity-and-improving-diet
25
Department of Health. Change4Life website at: http://www.nhs.uk/Change4Life/Pages/change-for-life.aspx
26
Department of Health. Press release: Final design of consistent nutritional labelling system given green light. Published 19 June 2013. Available at: https://www.gov.uk/government/news/final-design-of-consistent-nutritional-labelling-system-given-green-light
27
Department of Health. Public Health Responsibility Deal. Available at: https://responsibilitydeal.dh.gov.uk/
Department of Health. Guidance: UK physical activity guidelines. Published 11 July 2011. Available at: https://www.gov.uk/government/publications/uk-physical-activity-guidelines 28
29
J. Blundell, S. Coe, and B. Hooper. Conference Report: Food addiction – What is the evidence? Nutrition Bulletin, Volume 39, Issue 2, pages 218–222, June 2014. Article first published online: 19 MAY 2014 DOI: 10.1111/nbu.12092. Available at: http://onlinelibrary.wiley.com/doi/10.1111/nbu.12092/abstract?deniedAccessCustomisedMessage=&userIsAuthenticated=false 24 | WWW.PRIMARYCAREREPORTS.CO.UK
Primary Care Reports The leading specialist online research and networking resource for General Practitioners and other senior primary care professionals.
• Up to the minute news and other content available to all site users on a free-of-charge, open access basis. • Qualified signed up members are able to access premium content Special Reports and interact with their peers using a variety of advanced online networking tools. • Designed to help users identify new solutions, understand the implications of different choices and select the best options available. • Thought Leadership – Advice and guidance from internationally recognised primary care key opinion leaders. • Peer Input – Contributions from senior primary care professionals. • Independent Editorial Content – Expert and authoritative analysis from award winning journalists and leading industry commentators. • Unbiased Supplier Provided Content. • Designed to facilitate debate. • Written to the highest professional standards.
Visit: www.primarycarereports.co.uk